• 1
    Allender S, Scarborough P, Peto P et al. European Cardiovascular Disease Statistics. Brussels, Belgium: European Heart Network, 2008.
  • 2
    Unal B, Critchley JA, Capewell S. Explaining the decline in coronary heart disease mortality in England and Wales between 1981 and 2000. Circulation 2004; 109: 11017.
  • 3
    Ford ES, Ajani UA, Croft JB et al. Explaining the decrease in U.S. deaths from coronary disease, 1980–2000. N Engl J Med 2007; 356: 238898.
  • 4
    Bjorck L, Rosengren A, Bennett K, Lappas G, Capewell S. Modelling the decreasing coronary heart disease mortality in Sweden between 1986 and 2002. Eur Heart J 2009; 30: 104656.
  • 5
    Bennett K, Kabir Z, Unal B et al. Explaining the recent decrease in coronary heart disease mortality rates in Ireland, 1985–2000. J Epidemiol Community Health 2006; 60: 3227.
  • 6
    Unal B, Critchley JA, Capewell S. Modelling the decline in coronary heart disease deaths in England and Wales, 1981–2000: comparing contributions from primary prevention and secondary prevention. BMJ 2005; 331: 614.
  • 7
    Mant J, Hicks N. Detecting differences in quality of care: the sensitivity of measures of process and outcome in treating acute myocardial infarction. BMJ 1995; 311: 7936.
  • 8
    Goldman L, Cook EF. The decline in ischemic heart disease mortality rates. An analysis of the comparative effects of medical interventions and changes in lifestyle. Ann Intern Med 1984; 101: 82536.
  • 9
    Nichol MB, Venturini F, Sung JC. A critical evaluation of the methodology of the literature on medication compliance. Ann Pharmacother 1999; 33: 53140.
  • 10
    Boden WE, O’Rourke RA, Teo KK et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 2007; 356: 150316.
  • 11
    Briggs A, Sculpher M, Buxton M. Uncertainty in the economic evaluation of health care technologies: the role of sensitivity analysis. Health Econ 1994; 3: 95104.
  • 12
    Kabir Z, Bennett K, Shelley E et al. The population mortality benefits of maximizing the number of eligible patients receiving appropriate cardiology treatments in Ireland. QJM 2006; 99: 52330.
  • 13
    Capewell S, O’Flaherty M, Ford ES, Critchley JA. Potential reductions in United States coronary heart disease mortality by treating more patients. Am J Cardiol 2009; 103: 17039.
  • 14
    Capewell S, Unal B, Critchley JA, McMurray JJ. Over 20,000 avoidable coronary deaths in England and Wales in 2000: the failure to give effective treatments to many eligible patients. Heart 2006; 92: 5213.
  • 15
    Rosengren A, Eriksson H, Hansson PO et al. Obesity and trends in cardiovascular risk factors over 40 years in Swedish men aged 50. J Intern Med 2009; 266: 26876.
  • 16
    Green LA. Cholesterol-lowering therapy for primary prevention: Still much we don't know. Arch Intern Med 2010; 170:10078.
  • 17
    Shafazand M, Schaufelberger M, Lappas G, Swedberg K, Rosengren A. Survival trends in men and women with heart failure of ischaemic and non-ischaemic origin: data for the period 1987–2003 from the Swedish Hospital Discharge Registry. Eur Heart J 2009; 30: 6718.
  • 18
    Berg CM, Lissner L, Aires N et al. Trends in blood lipid levels, blood pressure, alcohol and smoking habits from 1985 to 2002: results from INTERGENE and GOT-MONICA. Eur J Cardiovasc Prev Rehabil 2005; 12: 11525.
  • 19
    Hippisley-Cox J, Coupland C. Effect of combinations of drugs on all cause mortality in patients with ischaemic heart disease: nested case-control analysis. BMJ 2005; 330: 105963.
  • 20
    McAlister FA. Commentary: relative treatment effects are consistent across the spectrum of underlying risks...usually. Int J Epidemiol 2002; 31: 767.
  • 21
    Myerson M, Coady S, Taylor H, Rosamond WD, Goff DC Jr. Declining severity of myocardial infarction from 1987 to 2002: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation 2009; 119: 50314.
  • 22
    Björck L, Wallentin L, Stenestrand U, Lappas G, Rosengren A. Medication in Relation to ST-Segment Elevation Myocardial Infarction in Patients With a First Myocardial Infarction: Swedish Register of Information and Knowledge About Swedish Heart Intensive Care Admissions (RIKS-HIA). Arch Intern Med 2010;170:137581.
  • 23
    Eliasson M, Janlert J, Jansson J-H. Time trends in population cholesterol levels 1986–2004: influence of lipid-lowering drugs, obesity, smoking and educational level. The northern Sweden MONICA study. JIM 2006; 260: 5519.
  • 24
    Schaufelberger M, Swedberg K, Koster M et al. Decreasing one-year mortality and hospitalization rates for heart failure in Sweden; Data from the Swedish Hospital Discharge Registry 1988 to 2000. Eur Heart J 2004; 25: 3007.
  • 25
    Walldius G, Jungner I, Holme I et al. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 2001; 358: 202633.
  • 26
    EUROASPIRE II Study Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J 2001;22:55472.
  • 27
    Dahlstrom U, Hakansson J, Swedberg K et al. Adequacy of diagnosis and treatment of chronic heart failure in primary health care in Sweden. Eur J Heart Fail 2009; 11: 928.
  • 28
    Cleland JG, Cohen-Solal A, Aguilar JC et al. Management of heart failure in primary care (the IMPROVEMENT of Heart Failure Programme): an international survey. Lancet 2002; 9346: 16319.
  • 29
    Estess JM, Topol EJ. Fibrinolytic treatment for elderly patients with acute myocardial infarction. Heart 2002; 87: 30811.
  • 30
    Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 7186.
  • 31
    Cucherat M, Bonnefoy E, Tremeau G. Primary angioplasty versus intravenous thrombolysis for acute myocardial infarction. Cochrane Database Syst Rev 2000; (2): CD001560.
  • 32
    Fox KA, Poole-Wilson P, Clayton TC et al. 5-year outcome of an interventional strategy in non-ST-elevation acute coronary syndrome: the British Heart Foundation RITA 3 randomised trial. Lancet 2005; 366: 91420.
  • 33
    Freemantle N, Cleland J, Young P, Mason J et al. beta Blockade after myocardial infarction: systematic review and meta regression analysis. BMJ 1999; 318: 17307.
  • 34
    Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. ACE Inhibitor Myocardial Infarction Collaborative Group. Circulation 1998;97:220212.
  • 35
    Nichol G, Stiell IG, Hebert P et al. What is the quality of life for survivors of cardiac arrest? A prospective study Acad Emerg Med 1999; 6: 95102.
  • 36
    Rea TD, Eisenberg MS, Culley LL et al. Dispatcher-assisted cardiopulmonary resuscitation and survival in cardiac arrest. Circulation 2001; 104: 25136.
  • 37
    Holmberg M, Holmberg S, Herlitz J et al. Survival after cardiac arrest outside hospital in Sweden. Swedish Cardiac Arrest Registry. Resuscitation 1998; 36: 2936.
  • 38
    Nadkarni VM, Larkin GL, Peberdy MA et al. First documented rhythm and clinical outcome from in-hospital cardiac arrest among children and adults. JAMA 2006; 295: 507.
  • 39
    Tunstall-Pedoe H, Bailey L, Chamberlain DA et al. Survey of 3765 cardiopulmonary resuscitations in British hospitals (the BRESUS Study): methods and overall results. BMJ 1992; 304: 134751.
  • 40
    Flather MD, Yusuf S, Kober L et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet 2000; 35: 157581.
  • 41
    Baigent C, Keech A, Kearney PM et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366: 126778.
  • 42
    Wilt TJ, Bloomfield HE, MacDonald R et al. Effectiveness of statin therapy in adults with coronary heart disease. Arch Intern Med 2004; 164: 142736.
  • 43
    Anand SS, Yusuf S. Oral anticoagulant therapy in patients with coronary artery disease: a meta-analysis. JAMA 1999; 282: 205867.
  • 44
    Lau J, Antman EM, Jimenez-Silva J et al. Cumulative meta-analysis of therapeutic trials for myocardial infarction. N Engl J Med 1992; 327: 24854.
  • 45
    Taylor RS, Brown A, Ebrahim S et al. Exercise-based rehabilitation for patients with coronary heart disease: systematic review and meta-analysis of randomized controlled trials. Am J Med 2004; 116: 68292.
  • 46
    Yusuf S, Zucker D, Peduzzi P et al. Effect of coronary artery bypass graft surgery on survival: overview of 10-year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration. Lancet 1994; 344: 56370.
  • 47
    Kaiser C, Brunner-La Rocca HP, Buser PT et al. Incremental cost-effectiveness of drug-eluting stents compared with a third-generation bare-metal stent in a real-world setting: randomised Basel Stent Kosten Effektivitats Trial (BASKET). Lancet 2005; 366: 9219.
  • 48
    Folland ED, Hartigan PM, Parisi AF. Percutaneous transluminal coronary angioplasty versus medical therapy for stable angina pectoris: outcomes for patients with double-vessel versus single-vessel coronary artery disease in a Veterans Affairs Cooperative randomized trial. Veterans Affairs ACME Investigators. J Am Coll Cardiol 1997; 29: 150511.
  • 49
    Pocock SJ, Henderson RA, Rickards AF et al. Meta-analysis of randomised trials comparing coronary angioplasty with bypass surgery. Lancet 1995; 346: 11849.
  • 50
    Bucher HC, Hengstler P, Schindler C et al. Percutaneous transluminal coronary angioplasty versus medical treatment for non-acute coronary heart disease: meta-analysis of randomised controlled trials. BMJ 2000; 321: 737.
  • 51
    Oler A, Whooley MA, Oler J, Grady D. Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. A meta-analysis. JAMA 1996; 276: 8115.
  • 52
    Boersma E, Harrington RA, Moliterno DJ et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet 2002; 359: 18998.
  • 53
    Shibata MC, Flather MD, Wang D. Systematic review of the impact of beta blockers on mortality and hospital admissions in heart failure. Eur J Heart Fail 2001; 3: 3517.
  • 54
    Pitt B, Zannad F, Remme WJ et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 70917.
  • 55
    Law M, Wald N, Morris J. Lowering blood pressure to prevent myocardial infarction and stroke: a new preventive strategy. Health Technol Assess 2003; 7: 194.
  • 56
    Pignone M, Phillips C, Mulrow C. Use of lipid lowering drugs for primary prevention of coronary heart disease: meta-analysis of randomised trials. BMJ 2000; 321: 9836.
  • 57
    Studer M, Briel M, Leimenstoll B et al. Effect of different antilipidemic agents and diets on mortality: a systematic review. Arch Intern Med 2005; 165: 72530.
  • 58
    Sculpher MJ, Seed P, Henderson RA et al. Health service costs of coronary angioplasty and coronary artery bypass surgery: the Randomised Intervention Treatment of Angina (RITA) trial. Lancet 1994; 344: 92730.
  • 59
    Hagman M, Jonsson D, Wilhelmsen L. Prevalence of angina pectoris and myocardial infarction in a general population sample of Swedish men. Acta Med Scand 1977; 201: 5717.
  • 60
    Capewell S, Beaglehole R, Seddon M et al. Explanation for the decline in coronary heart disease mortality rates in Auckland, New Zealand, between 1982 and 1993. Circulation 2000; 102: 15116.
  • 61
    Capewell S, Morrison CE, McMurray JJ. Contribution of modern cardiovascular treatment and risk factor changes to the decline in coronary heart disease mortality in Scotland between 1975 and 1994. Heart 1999; 81: 3806.